Innovative Antidepressants: Jumping out of the Monoamine-Based Theory?

Chun Yang,Wenyuan Li,Zhengdong Zhou,Jianjun Yang

DOI: https://doi.org/10.1517/14656566.2011.629032

2011-01-01

Expert Opinion on Pharmacotherapy

Abstract:Dear Editor, We read with great interest the review of agomelatine for the treatment of major depressive disorder by Carney et al. [1]. Agomelatine is a new antidepressant agent whose therapeutic effect does not depend on monoamine-based theory, the principal mechanism of conventional antidepressants, which dominates the field at present. Agomelatine is now on the market in 41 countries [1], which indicates potentially that it will bring us into a new epoch of non-monoamine antidepressants. Conventional antidepressants promote monoamines to exert their therapeutic effects, but their inherent adverse effects afflict depressed patients [2]. More importantly, monoaminergic antidepressants unfortunately have a delayed onset time of 2 -4 weeks and a low effective power of ~ 50%, implying that increasing monoamines may just be a partial, downstream and imperfect treatment [3]. However, agomelatine, with its melatonergic agonistic and 5-HT2C antagonistic properties, combines early depression relief with a favorable side-effect profile and long-lasting antidepressant efficacy [4]. The difference between these two kinds of antidepressant suggests that non-monoaminergic antidepressants hold promise in the near future. There is an urgent need for the development of more effective, more rapidly acting, safer and better-tolerated antidepressants. Indeed, besides the research in the improvement of conventional antidepressants, more studies are now directed towards finding antidepressants that act on non-monoaminergic targets, for example melatonergic, glutamatergic, cholinergic, purinergic, neurokinin, glucocorticoid and opioid receptors and mitochondrial activity.